Bullish
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics presented extended data from its Phase 1b clinical trial of anzu-cel (IMA203) PRAME TCR T-cell therapy for advanced melanoma at the 2026 ASCO...